This activity is designed for pulmonary providers who participate in the care of patients with pulmonary hypertension including general pulmonologists, interventional pulmonologists, thoracic surgeons, internal medicine primary care and other subspecialty providers, physicians-in-training, nurses including nurse navigators, nurse practitioners and physician extenders.
Upon completion of the educational activity, participants should be able to:
- Identify the 2018 World Symposium on Pulmonary Hypertension new thresholds for the normal range of pulmonary artery pressure to be used in the diagnosis of pulmonary hypertension.
- Delineate the diagnostic tests, NYHA and WHO classifications, and differential diagnostic considerations to provide a diagnosis of PAH.
- Develop treatment strategies for optimal management of patients with PH/PAH.
CME Credit provided by The American Thoracic Society
CME Accreditation Statement
The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Credit Designation Statement
The American Thoracic Society designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 1 Contact Hours.
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.
This activity is approved for 1 contact hour(s) which includes 0.5 hour(s) of pharmacology. Activity ID # 22027
This activity was planned in accordance with AANP Accreditation Standards and Policies.
This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and Bayer HealthCare Pharmaceuticals Inc.
Criteria for Success
Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test and submission of the activity evaluation form. A passing score of 70% on the quiz is required to receive credit. A certificate will be available in your transcripts upon successful completion of the quiz and evaluation. If you have questions about this CME/CE activity, please contact AKH Inc. at email@example.com. There is no fee for this activity.
ABOUT OUR FACULTY
Richard Channick, MD
Professor of Medicine
Saul Brandman Chair of Pulmonary Arterial Hypertension
Co-Director, Pulmonary Vascular Disease Program
Director, Acute Chronic Thromboembolic Disease
UCLA Medical Center
David Geffen School of Medicine
Los Angeles, CA
Richard Channick, MD, is Professor of Medicine and Saul Brandman Chair of Pulmonary Arterial Hypertension at David Geffen School of Medicine at UCLA. He serves as Co-Director of the Pulmonary Vascular Disease Program and Director of the Acute and Chronic Thromboembolic Disease at UCLA Medical Center. Dr. Channick received his medical degree from Temple University Medical School, where he was elected to the Alpha Omega Alpha Medical Honor Society. He did his residency and was Chief Resident at the University of Massachusetts Medical Center. He did a pulmonary and critical care fellowship at the University of California, San Diego Medical Center. Dr. Channick was at UCSD for 20 years helping build the pulmonary vascular program there. From 2009-2018 he was at Massachusetts General Hospital, Harvard Medical School where he built a large Pulmonary Vascular Program. He has been at UCLA since September 2018, directing the UCLA Acute and Chronic Thromboembolic Disease Program. Dr. Channick has published over 200 original articles, chapters and reviews focused on all aspects of pulmonary hypertension and pulmonary embolism. He serves on many national and international leadership committees including the American Thoracic Society Pulmonary Circulation Program Committee and the American College of Chest Physicians Pulmonary Vascular Disease Network steering committee, past Chair of the Scientific Leadership Committee. Dr. Channick has served on the steering committees for several pivotal clinical trials in pulmonary vascular disease and lectures nationally and internationally.
Vallerie V. McLaughlin, MD
Kim A. Eagle, MD Endowed
Professor of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Vallerie V. McLaughlin, MD, is the Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine, Director of the Pulmonary Hypertension Program, and Associate Chief of Cardiovascular Medicine at the University of Michigan, Ann Arbor. She is a Fellow of the American College of Cardiology, the American College of Chest Physicians and the American Heart Association, and is a member of the American Thoracic Society. She has served as Chair of the American Heart Association “Women in Cardiology” Committee and as a member of the American College of Cardiology Scientific Sessions Program Committee. Professor McLaughlin is a Past-Chair of the Scientific Leadership Council of the PH Association, Past-Editor-in-Chief of Advances in Pulmonary Hypertension. and Past-Chair of the PH Association Board of Trustees. She was Chair of the American College of Cardiology/American Heart Association Clinical Expert Consensus Document on PH. She was inaugurated as a charter member into the Clinical Excellence Society at the University of Michigan. Her research interests focus on PH.
Nadine Al-Naamani, MD, MS
Assistant Professor of Medicine
Hospital of the University of Pennsylvania
FACULTY AND PEER REVIEWER DISCLOSURES
Dr. Channick has disclosed the following relevant financial relationships:
Consultant - Actelion, Bayer, Gossamer, Theravance
Contracted Research - Bayer
Dr. McLaughlin has disclosed the following relevant financial relationships:
Consultant - Acceleron, Actelion, Altavant, Caremark, CiVi Biopharma, Gossamer Bio, Liquida, United Therapeutics
Contracted Research - Acceleron, Actelion, Gilead, Reata Phar, SonoVie, United Therapeutics
Nadine Al-Naamani, MD, MS - Peer Reviewer: has no financial relationships to disclose.
AKH STAFF AND PLANNERS DISCLOSURES
Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer: has no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.
ATS STAFF DISCLOSURES
Suzette Machado, MPA, CHCP, Associate Director of Education Programs and Accreditation; has no financial relationships to disclose.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS and AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of ATS and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by ATS and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.